Wasatch BioLabs Expands Service Portfolio with Oxford Nanopore Assays in Pharmacogenomics, Telomere Sequencing, and mRNA Vaccine Quality Control

SALT LAKE CITY, Oct. 6, 2025 /PRNewswire/ -- Wasatch BioLabs (WBL), a Renew Biotechnologies subsidiary, and the largest U.S. sequencing service provider dedicated exclusively to long-read sequencing, today announced the addition of three Oxford Nanopore–developed research-use-only (RUO) assays to its service portfolio: a Pharmacogenomics (PgX) panel, Telomere Sequencing, and mRNA Vaccine Quality Control. Headquartered in a 20,000sqft CLIA-registered laboratory, WBL combines Oxford Nanopore's assays with its proven expertise in long-read sequencing to deliver data at scale with clarity and actionable insight.

"By integrating these Oxford Nanopore assays into our services, we're giving translational teams a way to adopt these powerful workflows with confidence," said Steve Abbott, COO at Wasatch BioLabs. "Our expertise ensures the data is delivered with the quality, clarity, and scale needed to accelerate today's most important research."

Pharmacogenomics (PGx) Panel (RUO)
Developed by Oxford Nanopore, the PGxpanel delivers full-gene coverage – including repeats, structural variants, and hybrid alleles that are often missed by short-read methods. By offering the panel as a service, WBL enables researchers to generate more complete pharmacogenomic profiles with rapid turnaround and integrated bioinformatics, and offers fit-for-purpose validations to align with study needs and regulatory expectations. This higher-resolution approach strengthens precision medicine studies and drug development pipelines with greater confidence and reliability.

Telomere Sequencing (RUO)
ONT's telomere workflow provides molecule-level resolution of telomere length distributions and subtelomeric methylation across individual chromosome arms. WBL brings this assay to scale for oncology, aging, and rare disease programs where subtle telomere dynamics often hold critical biological meaning. With high precision, researchers can now incorporate telomere measurements into longitudinal studies and translational models with greater consistency.

mRNA Vaccine Quality Control
With long reads, single-molecule resolution, and no amplification artifacts, Wasatch BioLab's mRNA Vaccine QC service delivers a complete and accurate view of mRNA constructs, from early development through lot release and stability studies, all within a single streamlined workflow. This approach preserves critical features such as poly(A) tails, structural heterogeneity, and overall integrity to confirm product quality and support regulatory-ready development.

Applications and Access
Together, these assays expand WBL's ability to support BioPharma and Biotech teams across a wide spectrum of applications – from drug response studies, to telomere biology research, to mRNA vaccine development. With Oxford Nanopore's assays run through WBL's high-capacity infrastructure and expert bioinformatics pipelines, researchers gain access to advanced long-read workflows in a setting designed for both discovery and translational impact.

About Wasatch BioLabs
Wasatch BioLabs (WBL) is the largest U.S. sequencing service provider exclusively specialized in long-read sequencing. Operating out of Salt Lake City, WBL combines state-of-the-art laboratories, audit-ready quality systems, and high-throughput processing capacity. WBL partners with BioPharma, Biotech, and academic teams to deliver sequencing solutions across genomic, transcriptomic, and epigenetic applications.

For more information, please visit www.wasatchbiolabs.com.

SOURCE Wasatch BioLabs